IMNM Immunome, Inc.
USHealthcareAs of 2026-07-10 16:00
Why IMNM matters now
Immunome, Inc. (IMNM) is a US stock in Healthcare. The latest InvestLog snapshot shows $23.35 with -3.39% on the session and $2.23B in market capitalization; recent performance reads 1-month -4.68% and YTD -12.76%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-53.8M, and EPS of $-0.48. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.5%.
The latest indexable market news headline is "Immunome Stock Up 32% in a Month: Here's What You Should Know" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $36.50; recent insider activity includes Rosett Max filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.60
P/S
446.19
EV/EBITDA
-5.47
DCF Value
$7.38
FCF Yield
-11.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1161.9%
Operating Margin
-5947.9%
Net Margin
-5593.8%
ROE
-51.2%
ROA
-36.2%
ROIC
-40.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-53.8M | $-0.48 |
| Q4 2025 | $0.00 | $-69.9M | $-0.76 |
| FY 2025 | $6.9M | $-212.4M | $-2.43 |
| Q3 2025 | $0.00 | $-57.5M | $-0.65 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$36.50
Target (Median)
$36.50
Target Range
$33.00 - $40.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.07
Immunome, Inc. functions as a biopharmaceutical company dedicated to the discovery and advancement of antibody-based therapies for both cancer and infectious illnesses. A pivotal project in its oncology portfolio is IMM-ONC-01, which is engineered to target the IL-38 immune checkpoint – a protein originating from tumors that enables cancer cells to bypass the body's immune surveillance. Additionally, the company is developing IMM-BCP-01, an experimental antibody cocktail designed for the management of SARS-CoV-2 infections and COVID-19. This enterprise was founded in 2006 and its principal operations are based in Exton, Pennsylvania.